United Therapeutics Corporation $UTHR Stake Raised by Tobam

Tobam boosted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 28.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,857 shares of the biotechnology company’s stock after acquiring an additional 2,211 shares during the quarter. Tobam’s holdings in United Therapeutics were worth $4,803,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Geneos Wealth Management Inc. boosted its holdings in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 70 shares during the period. Jump Financial LLC acquired a new position in United Therapeutics in the 2nd quarter valued at approximately $277,000. Cerity Partners LLC lifted its position in United Therapeutics by 77.3% in the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after buying an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia lifted its position in United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after buying an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of several research analyst reports. Bank of America boosted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. HC Wainwright lifted their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Royal Bank Of Canada lowered their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. UBS Group raised their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $619.42.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,540,358.40. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 644,468 shares of company stock valued at $364,004,497 in the last three months. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR opened at $536.59 on Friday. The stock’s 50-day moving average price is $564.47 and its 200 day moving average price is $523.41. The firm has a market capitalization of $22.78 billion, a price-to-earnings ratio of 19.81, a P/E/G ratio of 1.75 and a beta of 0.57. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the prior year, the business posted $6.63 EPS. United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. Equities research analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.